Steve Bryson, PhD, science writer —

People with acute intermittent porphyria (AIP) who were treated with Alnylam Pharmaceuticals’ RNA-based therapy Givlaari (givosiran) had a 74% reduction in porphyria attacks and sustained decreases in toxic products over six…

Two previously unreported mutations were found in a man and his mother with variegate porphyria affecting the skin only, a new case study reports.  This finding may help healthcare professionals better understand the connection between specific genetic mutations and disease development…